7-Aug-2026
Globe Newswire (Tue, 4-Aug 8:50 AM ET)
Globe Newswire (Wed, 22-Jul 8:40 AM ET)
Akari Therapeutics Enters Strategic Research Collaboration with Whitehawk Therapeutics
Globe Newswire (Tue, 21-Jul 7:05 AM ET)
Globe Newswire (Tue, 7-Jul 8:55 AM ET)
Globe Newswire (Mon, 29-Jun 8:45 AM ET)
Globe Newswire (Thu, 4-Jun 9:30 AM ET)
Market Chameleon (Thu, 28-May 7:06 AM ET)
Globe Newswire (Thu, 28-May 9:17 AM ET)
Market Chameleon (Fri, 22-May 5:52 AM ET)
Market Chameleon (Fri, 22-May 3:05 AM ET)
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.
Akari Therapeutics PLC - American Depositary Shares trades on the NASDAQ stock market under the symbol AKTX.
As of August 7, 2026, AKTX stock price declined to $7.00 with 22,058 million shares trading.
AKTX has a beta of 3.02, meaning it tends to be more sensitive to market movements. AKTX has a correlation of 0.03 to the broad based SPY ETF.
AKTX has a market cap of $12.25 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, AKTX traded as high as $219.20 and as low as $3.02.
AKTX has underperformed the market in the last year with a price return of -82.7% while the SPY ETF gained +23.5%. However, in the short term, AKTX had mixed performance relative to the market. It has outperformed in the last 3 months, returning +6.4% vs +6.0% return in SPY. But in the last 2 weeks, AKTX shares have been beat by the market, returning -19.5% compared to an SPY return of +4.6%.
AKTX support price is $7.32 and resistance is $8.85 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AKTX shares will trade within this expected range on the day.